TLR4 and metabolic dysfunction-associated steatotic liver disease: Similarly, increases in hepatic tenascin-C expression occur in obese individuals with non-alcoholic fatty liver disease (NAFLD) [34], and in each of these scenarios tenascin-C interacts with TLR4 to augment local tissue inflammation.